Cartas al Editor 111 5.- Hernández-Rocha C, Ibáñez P, Molina ME, Klassen J, Valenzuela A, Candia R, et al. Diagnóstico y manejo de colitis ulcerosa grave. Una mirada actualizada. Rev Med Chile 2017; 145: 96-105. 6.- Pizarro G, Castro L, Hernández E, Pérez T, Quera R. Manejo de la colitis ulcerosa grave: experiencia a partir de un hospital ministerial. Gastroenterol latinoam 2014; 25: 71-8. 7.- Ho GT, Soranzo N, Nimmo ER, Tenesa A, Goldstein DB, Satsangi J. ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Moll Genet 2006; 15: 797-805. 8.- Michail S, Durbin M, Turner D, Griffiths AM, Mack DR, Hyams J, et al. Alterations in the gut microbiomes of children with severe ulcerative colitis. Inflamm Bowel Dis 2012; 18: 1799-808. 9.- Travis SP, Farrant JM, Ricketts C, Nolan DJ, Mortensen NM, Kettlewell MG, et al. Predicting the outcome of severe ulcerative colitis. Gut 1996; 38: 905-10. 10.- Ho GT, Mowat C, Goddard CJ, Fennell JM, Shah NB, Prescott RJ, et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-87. 11.- Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther 2016; 43: 482-513. 12.- Lynch RW, Churchhouse AM, Protheroe A, Arnott DR. Predicting outcome in acute severe ulcerative colitis: comparison of the Travis and Ho scores using IBD audit data. Aliment Pharmacol The 2016; 43: 1132-41. 13.- Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, openlabel randomized controlled trial. Lancet 2012; 380: 1909-15. 14.- Walch A, Meshkat M, Vogelsang H, Novacek G, Dejaco C, Angelberger S, et al. Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines. J Crohns Colitis 2010; 4: 398-404. 15.- Gibson DJ, Heetun ZS, Redmond CE, Nanda KS, Keegan D, Byrne K, et al. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-5. 16.- Ordas I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-base dosing paradigms. Clinical Pharmacol Ther 2012; 91: 635-46. 17.- Theede K, Holck S, Ibsen P, Ladelund S, Nordgaard-Lassen I, Nielsen A. Level of fecal calprotectin correlates with endoscopic and histologic inflammation and identifies patients with mucosal healing in ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 1929-36. 18.- Sipponen T, Kolho KL. Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease. Scand J Gastroenterol 2015; 50: 74-80. 19.- Ho GT, Lee HM, Brydon G, Ting T, Hare N, Drummond H, et al. Fecal calprotectin predicts the clinical course of acute severe ulcerative colitis. Am J Gastroenterol 2009; 104: 673-8. 20.- Calafat M, Cabré E, Mañosa M, Lobatón T, Marín L, Domènech E. High within-day variability of fecal calprotectin levels in patients with active Ulcerative Colitis: What is the best timing for stool sampling? Inflamm Bowel Dis 2015; 21: 1072-6. 21.- Vuitton L, Peyrin-Biroulet L, Colombel JL, Pariente B, Pineton de Chambrun G, Walsh AJ, et al. Defining endoscopic response and remission in ulcerative colitis clinical trials: an international consensus. Aliment Pharmacol Ther 2017; 45: 801-13. 22.- Corte C, Fernandopulle N, Catuneanu AM, Burger D, Cesarini M, White L, et al. Association between the ulcerative colitis endoscopic index of severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015; 9: 376-81. 23.- Fernandes SR, Santos PM, Moura CM, Marques da Costa P, Carvalho JR, Valente AI, et al. The use of a segmental endoscopic score may improve the prediction of clinical outcomes in acute severe ulcerative colitis. Rev Esp Enferm Dig 2016; 108: 697-702. 24.- Wichmann A, Kinnucan J, Rubin DT. Novel use of cyclosporine inclusion therapy as a bridge to vedolizumab in severe ulcerative colitis. Inflamm Bowel Dis 2014; 20 (Suppl 1): S22. 25.- Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol 2016; 1: 15-24. 26.- Molnár T, Farkas K, Szepes Z, Nagy F, Szüccs M, Nyári T, et al. Long-term outcome of cyclosporin rescue therapy in acute, steroid refractory severe ulcerative colitis. United Eur Gastroenterol J 2014; 2: 108-12. 27.- Schmidt KJ, Müller N, Dignass A, Baumgart DC, Lehnert H, Stange EF, et al. Long-term in steroid refractory ulcerative colitis treated with tacrolimus alone or in combination with purine analogues. J Crohns Colitis 2016; 10: 31-7. 28.- Lawrance IC, Baird A, Lightower D, Radford-Smith G, Andrews JM, Connor S. Efficacy of rectal tacrolimus for induction therapy in patients with resistant ulcerative proctitis. Clin Gastroenterol Hepatol 2017 Mar 7. 29.- Macaluso FS, Renna S, Orlando A, Cottone M. The biologics of ulcerative colitis. Expert Opinion Biol Ther 2017; 17: 175-84. 30.- Rosen MJ, Minar P, Vinks AA. Review article: applying pharmacokinetics to optimize dosing of anti-TNF biologics in acute severe ulcerative colitis. Aliment Pharmacol Ther 2015; 41: 1094-103. 31.- Yarur AJ, Jain A, Sussman DA, Barkin JS, Quintero MA, Princen F, et al. The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: The ATLAS study. Gut 2016; 65: 249-55. 32.- Brandse S JF, van der Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology 2015; 149: 350-5. Colitis u lcerosa gra ve - C. Estay H. et al. Gastroenterol. latinoam 2017; Vol 28, Nº 2: 107-112
gastrolat 2 2017
To see the actual publication please follow the link above